Mirum Pharmaceuticals Provides Development Program Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Citi Reiterates Buy Rating on Mirum (MIRM), PT $34, 'Volixibat ICP Trial Discontinued, PSC and PBC Readouts Remain On Track'
November 29, 2022 9:05 AM UTCCiti analyst David Lebowitz reiterated a Buy rating and $34.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)
The analyst comments "Today, Mirum announced the discontinuation of Phase IIb OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to challenges in... More
